Induction Therapy in Transplant-Ineligible NDMM

EP: 1.State of The Art in Multiple Myeloma: Year in Review 2022

EP: 2.Induction Regimen Options in Transplant-Eligible NDMM

EP: 3.DETERMINATION, GRIFFIN, and MASTER Studies

EP: 4.Role of Transplant and Induction Therapies in NDMM

Now Viewing

EP: 5.Induction Therapy in Transplant-Ineligible NDMM

EP: 6.Clinical Trials in Transplant-Ineligible NDMM

EP: 7.Review of Patient Subgroups in Transplant-Ineligible NDMM

EP: 8.Final Thoughts on Transplant-Ineligible Patients with MM

EP: 9.Treatment Approaches for Patients with Relapsed-Refractory MM

EP: 10.Treatment Selection of Bispecifics in Relapsed-Refractory MM

EP: 11.Rationale for Bispecific-Based Combinations in MM

EP: 12.The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options

EP: 13.Management of Bispecific Toxicities and Final Thoughts on Treatments in MM

EP: 14.Evaluating Treatment Options by Patient Type in Multiple Myeloma

Transcript:

Robert Z. Orlowski, MD: Let’s move on to transplant-ineligible patients. Cesar, give us an overview of some of the options for induction therapy.

Cesar Rodriguez, MD: There have been a lot of changes in terms of transplant-ineligible patients and how we’re going to manage these patients. We were used to doing melphalan for patients who weren’t going to go to transplant because we weren’t concerned about the ability to collect the stem cells. But since then, we have all these new agents. We have SWOG-S0777, which compared Rd [lenalidomide, dexamethasone] with VRd [bortezomib, lenalidomide, dexamethasone], showing that VRd [bortezomib, lenalidomide, dexamethasone] had a benefit in terms of the PFS [progression-free survival]. That became the new standard in people who were transplant ineligible.

Then the group from Boston [Massachusetts] and Wake Forest [University School of Medicine in Winston-Salem, North Carolina] started to do a spin-off of VRd [bortezomib, lenalidomide, dexamethasone] and VRd [bortezomib, lenalidomide, dexamethasone]–lite to see if that was better tolerated and had the same responses or was comparable. That’s something we’ve been adopting in our practice. Nowadays, with the anti-CD38s, we have the data of the MAIA study. That compared lenalidomide-dexamethasone vs daratumumab, lenalidomide, and dexamethasone, showing a benefit of adding daratumumab to this and a good option for transplant-ineligible [patients].

Transcript edited for clarity.